Lyon, France – 21 March 2017 – NETRIS Pharma Starts Enrollment of First Clinical Study to Evaluate Drug Candidate Targeting Dependence Receptors.
NETRIS Pharma, a pioneer in the development of dependence receptor targeted cancer medicines, announced today the start of enrollment of patients with advanced/metastatic solid tumors in its Phase I clinical study of NP137, a humanized monoclonal antibody targeting Netrin-1 (NCT02977195). The study represents the first time a drug candidate targeting dependence receptors has been evaluated in humans. Dependence receptors are tumor suppressors that trigger cell death unless engaged by a ligand, in this case Netrin-1. Blocking Netrin-1 could re-introduce the natural tumor cell death pathway.
Further information at :